CA2212339A1 - Methods of inhibiting cell-cell adhesion - Google Patents
Methods of inhibiting cell-cell adhesionInfo
- Publication number
- CA2212339A1 CA2212339A1 CA002212339A CA2212339A CA2212339A1 CA 2212339 A1 CA2212339 A1 CA 2212339A1 CA 002212339 A CA002212339 A CA 002212339A CA 2212339 A CA2212339 A CA 2212339A CA 2212339 A1 CA2212339 A1 CA 2212339A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- cell
- cells
- adhesion
- cell adhesion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyrrole Compounds (AREA)
Abstract
A method of inhibiting cell-cell adhesion comprising administering to a human in need thereof an effective amount of a compound having formula (I), wherein R1 and R3 are independently hydrogen, -CH3, (a), or (b), wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
Description
CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 METHODS OF INHIBITING CELL-CELL ADHESION
The vascular endothelium constitutes a major organ that functions as a regulator of blood coagulation, inflammation and in the exchange of fluids and mediators between the intravascular compartment and parenchyma tissues. AS such, the proper function of the endothelium is critical to overall homeostasis. A dysfunction of the endothelium resulting from an alteration in the expression of important surface molecules, can result in coagulation defects, local and systemic vascular inflammation, and enhancement in the progression and rupture of atherosclerotic plaque. These effects can further result in conditions including myocardial infarction, deep venous thrombosis, disseminated intravascular thrombosis, and stroke.
Certain cell surface proteins are altered in response to a vascular injury or insult, and can be used as markers of a dysfunctional endothelium. A critical class of such proteins is the receptors/ligands mediating cell-cell adhesion, including the integrins, selectins (e.g. ELAM) and members of the immunoglobulin superfamily such as ICAM and VCAM. These molecules are increased in response to a variety of stimuli including cytokines, and in addition to being important markers of a dysfunctional endothelium, play a key role in thrombotic, inflammatory and atherogenic processes in the vascular wall. Other activities, such as surface anticoagulant responses, are also impaired in states of endothelial dysfunction. A compound that could block endothelial dys~unction, as determined by measuring it ability to inhibit cell-cell adhesion or expression of procoagulant activities, could be useful in treating conditions such as sepsis, injuries involving major tissue damage and trauma, systemic inflammatory response syndrome, sepsis syndrome, septic shock and multiple organ dysfunction syndrome including DIC) as well as atherosclerotic plaque CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 rupture and its associated sequela. Because cell-cell adhesion is a fundamental process of broad biological importance, the ability to specifically modulate adhesive proteins has the potential for many clinical applications outside of the vascular tissue including its use as an anti-inflammatory agent.
This invention provides methods ~or inhibiting cell-cell adhesion comprising administering to a human need thereof an effective amount of a compound of formula I
~ OCH,CH,-R~
RlO ~ ~ OR3 (I) wherein Rl and R3 are independently hydrogen, -CH3, O O
-C-(Cl-Ch alkyl), or C-Ar , wherein Ar is optionally substituted phenyl;
R2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; and pharmaceutically acceptable salts and solvates thereof.
The current invention concerns the discovery that a select group of 2-phenyl-3-aroylbenzothiophenes (benzothiophenes), those of formula I, are useful for inhibiting cell-cell adhesion, and particularly, vascular cell-cell adhesion. Also, the compounds are useful for inhibiting vascular endothelium dysfunction.
The methods of use provided by this invention are practiced by administering to a human in need thereof a dose CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/026S7 of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof, that is effective to inhibit cell-cell adhesion or its effects. The term ~inhibit" includes its generally accepted meaning which includes prohibiting, preventing, restraining, and slowing, stopping or reversing.
As such, the present method includes both medical therapeutic and/or prophylactic administration, as appropriate.
Raloxifene, a compound of this invention wherein it is the hydrochloride salt of a compound of formula 1, R1 and R3 are hydrogen and R2 is 1-piperidinyl, is a nuclear regulatory molecule. Raloxifene has been shown to bind to the estrogen receptor and was originally thought to be a molecule whose function and pharmacology was that of an anti-estrogen in that it blocked the ability of estrogen to activate uterine tissue and estrogen dependent breast cancers. Indeed, raloxifene does block the action of estrogen in some cells; however in other cell types, raloxifene activates the same genes as estrogen does and displays the same pharmacology, e.g., osteoporosis, hyperlipidemia. As a result, raloxifene has been referred to as an anti-estrogen with mixed agonist-antagonist properties.
The unique profile which raloxifene displays and differs from that of estrogen is now thought to be due to the unique activation and/or suppression of various gene functions by the raloxifene-estrogen receptor complex as opposed to the activation and/or suppression of genes by the estrogen-estrogen receptor complex. Therefore, although raloxifene and estrogen utilize and compete for the same receptor, the pharmacological outcome from gene regulation of the two is not easily predicted and is unique to each.
Generally, the compound is formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered by the intramuscular or intravenous routes. The compounds can be administered CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 transdermally, and may be formulated as sustained release dosage ~orms and the like.
The compounds used in the methods o~ the current invention can be made according to established procedures, such as those detailed in U.S. Patent Mos. 4,133,814, 4,418,068, and 4,380,635 all o~ which are incorporated by re~erence herein. In general, the process starts with a benzo[b]thiophene having a 6-hydroxyl group and a 2-(4-hydroxyphenyl) group. The starting compound is protected, acylated, and deprotected to ~orm the ~ormula I compounds.
Examples of the preparation of such compounds are provided in the U.S. patents discussed above. Optionally substituted phenyl includes phenyl and phenyl substituted once or twice with Cl-C6 alkyl, Cl-C4 alkoxy, hydroxy, nitro, chloro, ~luoro, or tri(chloro or ~luoro)methyl.
The compounds used in the methods o~ this invention ~orm pharmaceutically acceptable acid and base addition salts with a wide variety o~ organic and inorganic acids and bases and include the physiologically acceptable salts which are o~ten used in pharmaceutical chemistry. Such salts are also part o~ this invention. Typical inorganic acids used to ~orm such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sul~uric, phosphoric, hypophosphoric and the like.
Salts derived ~rom organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkanoic ~and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sul~onic acids, may also be used.
Such pharmaceutically acceptable salts thus include acetate, phenylacetate, tri~luoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphth~l~ne-2-benzoate, bromide, isobutyrate, phenylbutyrate, ~-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, caprate, caprylate, chloride, cinn~m~te, citrate, ~ormate, ~umarate, glycollate, heptanoate, hippurate, lactate, malate, CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzene-sulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like.
A preferred salt is the hydrochloride salt.
The pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid. The reactants are generally combined in a mutual solvent such as diethyl ether or benzene. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.
Bases commonly used for formation of salts include ammonium hydroxide and alkali and alkaline earth metal hydroxides, carbonates, as well as aliphatic and primary, secondary and tertiary amines, aliphatic diamines. sases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, methylamine, diethylamine, ethylene diamine and cyclohexylamine.
The pharmaceutically acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more ~m~n~hle to formulation as liquids or emulsions.
Pharmaceutical formulations can be prepared by procedures known in the art. For example, the compounds can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the 'e following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents ~or retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate;
adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols.
The compounds can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes.
Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like. The formulations can be so constituted that they release the active ingredient only or pre~erably in a particular part o~
the intestinal tract, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.
The particular dosage of a compound of formula I
required to inhibit cell-cell adhesion or its effects, or any other use disclosed herein, and according to this invention will depend upon the severity of the condition, the route of administration, and related factors that will be decided by the attending physician. Generally, accepted and effective daily doses will be from about 0.1 to about 1000 mg/day, and more typically from about 50 to about 200 mg/day. Such dosages will be administered ~o a subject in need thereof from once to about three times each day, or more often as CA 022l2339 l997-08-0~
W 096/24384 PCTrUS96/02657 needed to effectively inhibit cell-cell adhesion or its effects, or any other use disclosed herein.
It is usually preferred to administer a compound of formula I in the form of an acid addition salt, as is customary in the administration of pharmaceuticals bearing a basic group, such as the piperidino ring. It is also advantageous to administer such a compound by the oral route.
For such purposes the following oral dosage forms are available.
Formulations In the formulations which follow, ~Active ingredientll means a compound of formula I.
Formulation 1: Gelatin Capsules Hard gelatin capsules are prepared using the following:
Ingredient Quantity (mg/capsule) Active ingredient0.1 - 1000 Starch, NF O - 650 Starch flowable powder 0 - 650 Silicone fluid 3S0 centistokes 0 - 15 The ingredients are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules.
Examples of specific capsule formulations of raloxifene that have been made include those shown below:
CA 022l2339 l997-08-0~
W O 96/24384 PC~rnUS96/02657 Formulation 2: Raloxifene capsule Ingredient Quantity (mg/capsule) Raloxifene Starch, NF 112 Starch ~lowable powder 225.3 Silicone ~luid 350 centistokes 1.7 Formulation 3: Raloxi~ene capsule s IngredientQuantitv (mg/capsule) Raloxifene 5 Starch, NF 108 Starch ~lowable powder225.3 Silicone fluid 350 centistokes 1.7 Formulation 4: Raloxi~ene capsule InaredientQuantitv (ma/capsule) Raloxi~ene 10 Starch, NF 103 Starch flowable powder225.3 Silicone ~luid 350 centistokes 1.7 Formulation 5: Raloxifene capsule IngredientQuantitv (mg~capsule) Raloxi~ene 50 Starch, NF 150 Starch ~lowable powder397 Silicone ~luid 350 centistokes 3.0 The speci~ic ~ormulations above may be changed in compliance with the reasonable variations provided.
CA 022l2339 l997-08-0~
W O 96/24384 PC~rrUS96/026S7 _g _ A tablet formulation is prepared using the ingredients below:
Formulation 6: Tablets Ingredient Quantitv tmg/tablet) Active ingredient 0.1 - 1000 Cellulose, microcrystalline 0 - 650 Silicon dioxide, fumed0 - 650 Stearate acid 0 - 15 The components are blended and compressed to form tablets.
Alternatively, tablets each containing 0.1 - 1000 mg of active ingredient are made up as follows:
Formulation 7: Tablets Inaredient Quantitv (ma/tablet) Active ingredient 0.1 - 1000 Starch 45 Cellulose, microcrystalline 35 Polyvinylpyrrolidone 4 (as 10% solution in water) Sodium carboxymethyl cellulose 4.5 Magnesium ctearate 0 5 Talc The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
The solution o~ polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50~-60~ C
- ~ and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 to the granules which, after mixing, are compressed on a tablet machine to yield tablets.
Suspensions each containing 0.1 - 1000 mg of medicament per 5 mL dose are made as follows:
Formulation 8: Suspensions Inaredient Quantity (mg/5 ml) Active ingredient 0.1 - 1000 mg Sodium carboxymethyl cellulose 50 mg Syrup 1.25 mg Benzoic acid solution 0.10 mL
Flavor q.v.
Color ~q.v.
Puri~ied water to 5 mL
The medicament is passed through a No. 45 me~sh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.
In vitro Cell Adhesion AssaYs Human Umbilical Vein Endothelium Cells (H W EC) or Human Aortic Endothelium (HAE) were obtained from Clonetics (San Diego) and grown in the EBM medium supplied by Clonetics. Cells were plated in 96 well plates at a density to obtain confluent monolayers following overnight incubation at 37 degrees C. Test compound was added and incubated in serum-free medium for 8-20 hours. Monolayers were then incubated with or without 2ng/ml IL-1 or with 20 nanograms Tumor Necrosis Factor (TNF) for 4 to 24 hours prior to the binding assay in a total volume of 75 to 100 microliters-in the presence o~ the test compound. Following incubations, CA 02212339 1997-08-0~
tritium-labelled U937 cells were added in 50 microliter ~ volumes at from 1 to 3 x 10(6) cells per well. The U937 cells were tritium labelled by the addition of 3H-thymidine - to a final concentration of 1 microcurie per milliliter, followed by 18 to 20 hours incubation. Cells were washed with PBS prior to use to remove excess label. After a 20 minute incubation of the labeled U937 cells with the endothelial cells, the wells were aspirated and washed four times with calcium-containing PBS. The monolayer and adherent U937 cells were solubilized by the addition of 0.25 SDS/0.1 N NaOH for 5 minutes with agitation. The level of binding was determined by scintillation counting of the solubilized cells.
Anticoaaulant activitv assaY
Confluent cultures of IL1-treated (2 ng/ml) or untreated human endothelial cells in 96 well plates were washed once with HBSS to remove serum proteins and incubated with serum-free medium (DMEM/F-12 medium, 20 mM-HEPES, pH 7.5, 50 mg/ml gentamicin, 1 mg/ml human transferrin and 1 mg/ml bovine insulin. ) containing 400 nM-recombinant human protein C and 10 nM human thrombin. Cells were incubated at 37~C, and at various times medium was removed and added to an equal volume of a solution of 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mg/ml sSA and 10 U/ml Hirudin. The samples were incubated in the hirudin-contain buffer for 5 min to inhibit thrombin activity. The amount of activated protein C generated was determined by the addition of chromogenic substrate (S-2366) to a final concentration of 0.75 mM, and measuring the change in absorbance units/minute at ~05 nm in a ThermoMax kinetic micro-titer plate reader (Molecular Devices). In all experiments, samples of the protein C/thrombin solution were incubated in wells without cells to determine basal levels of = = = ~ ~ = --CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 thrombin-catalyzed activation of protein C. The amount of activated protein C generated is expressed as the absorbance (mOD) per minute per microgram o~ cellular protein.
Results Human umbilical vein endothelial cells (H W EC) were treated with compound A where Rl and R3 are hydrogen and R3 is pyrrolidino, concurrent to the induction of adhesion molecule expression by TNF. As shown in Table I, the presence of 100 nM of compound A resulted in an approximate 40% reduction in the level of cell-cell adhesion in this assay. When cells were pretreated with only 10nM of compound A for approximately 20 hours before induction with TNF, an approximate 65 % reduction in adhesion was observed (TabIe 2). We also treated both HUVECs and human aortic endothelial cells (HAEC) with ILl, another inflammatory mediator to induce adhesion molecule expression in the presence of lOnM compound A. As shown in Table 3, compound A effectively inhibited the ILl-induction of adhesion in both cell Lines. Thus compound A can block the induction of adhesion molecule expression mediated by two independent means and in both venous and arterial cells.
As further evidence for the ability of this compound to modulate the functional properties of the endothelium, we measured the ability of the endothelial cells to activate human protein C, a natural regulatory function that is down regulated during states of endothelial dysfunction. AS shown in Table 4, ILl treatment of the cells significantly reduced the capability of the endothelium to support protein C
generation. However, following treatment of the cells with compound A, the suppression of this ~unction by ILl was essentially eliminated. The above data indicate that compound A protects the cells from activation of inflammatory and procoagulant activities.
CA 022l2339 l997-08-05 W 096/24384 PCTrUS96/02657 Table 1. E~ect of Compound A on adhesion of U937 cells to TNF-activated human umbilical vein endothelial cells (HUVEC) Condition Percent Binding Activity a Untreated control o + 7.5 TNF treated 100 + 9. 5 TNF plus compound A (100 nM) 62 + 17 aThe level of binding is expressed as the percent of the number of U937 cells bound to the endothelium before and after TNF induction.
Table 2. E~ect o~ pretreatment with compound A on adhesion o~ U937 cells to TNF-activated human umbilical vein endothelial cells (HUVEC) Condition ~ Percent Binding Activity a Untreated control 0 + 20 TNF treated 100 + 16 TNF plus compound A (10 nM) 34 + 8 CA 022l2339 l997-08-0~
W 096/24384 PCTnUS96/02657 aThe level of binding is expressed as the percent of the number of U937 cells bound to the endothelium before and after TNF induction.
Table 3. E~ect o~ pretreatment with compound A on adhesion o~ U937 cells to ILl -activated human aortic endothelial cells (HAEC) and human umbilical vein endothelial cells (HUVEC) Condition Percent 3inding Activitya to H W EC HAEC
ILl-treated 100 + 14 100 + 8 ILl plus compound A (10 nM) 18 + 13 54 i 7 aThe level of binding is expressed as the percent of the number of U937 cells bound to the endothelium before and after ILl induction.
Table 4. Ef~ect o~ compound A on thrombin-catalyzed activation o~ human protein C on endothelial cells treated with IL-l Condition Level of protein C produced (mOD/min/ug) untreated control 8.8 i 1. 4 l-treated 3.7 + 0.4 ILl plus compound A 7.6 + .6
W 096/24384 PCTrUS96/02657 METHODS OF INHIBITING CELL-CELL ADHESION
The vascular endothelium constitutes a major organ that functions as a regulator of blood coagulation, inflammation and in the exchange of fluids and mediators between the intravascular compartment and parenchyma tissues. AS such, the proper function of the endothelium is critical to overall homeostasis. A dysfunction of the endothelium resulting from an alteration in the expression of important surface molecules, can result in coagulation defects, local and systemic vascular inflammation, and enhancement in the progression and rupture of atherosclerotic plaque. These effects can further result in conditions including myocardial infarction, deep venous thrombosis, disseminated intravascular thrombosis, and stroke.
Certain cell surface proteins are altered in response to a vascular injury or insult, and can be used as markers of a dysfunctional endothelium. A critical class of such proteins is the receptors/ligands mediating cell-cell adhesion, including the integrins, selectins (e.g. ELAM) and members of the immunoglobulin superfamily such as ICAM and VCAM. These molecules are increased in response to a variety of stimuli including cytokines, and in addition to being important markers of a dysfunctional endothelium, play a key role in thrombotic, inflammatory and atherogenic processes in the vascular wall. Other activities, such as surface anticoagulant responses, are also impaired in states of endothelial dysfunction. A compound that could block endothelial dys~unction, as determined by measuring it ability to inhibit cell-cell adhesion or expression of procoagulant activities, could be useful in treating conditions such as sepsis, injuries involving major tissue damage and trauma, systemic inflammatory response syndrome, sepsis syndrome, septic shock and multiple organ dysfunction syndrome including DIC) as well as atherosclerotic plaque CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 rupture and its associated sequela. Because cell-cell adhesion is a fundamental process of broad biological importance, the ability to specifically modulate adhesive proteins has the potential for many clinical applications outside of the vascular tissue including its use as an anti-inflammatory agent.
This invention provides methods ~or inhibiting cell-cell adhesion comprising administering to a human need thereof an effective amount of a compound of formula I
~ OCH,CH,-R~
RlO ~ ~ OR3 (I) wherein Rl and R3 are independently hydrogen, -CH3, O O
-C-(Cl-Ch alkyl), or C-Ar , wherein Ar is optionally substituted phenyl;
R2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; and pharmaceutically acceptable salts and solvates thereof.
The current invention concerns the discovery that a select group of 2-phenyl-3-aroylbenzothiophenes (benzothiophenes), those of formula I, are useful for inhibiting cell-cell adhesion, and particularly, vascular cell-cell adhesion. Also, the compounds are useful for inhibiting vascular endothelium dysfunction.
The methods of use provided by this invention are practiced by administering to a human in need thereof a dose CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/026S7 of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof, that is effective to inhibit cell-cell adhesion or its effects. The term ~inhibit" includes its generally accepted meaning which includes prohibiting, preventing, restraining, and slowing, stopping or reversing.
As such, the present method includes both medical therapeutic and/or prophylactic administration, as appropriate.
Raloxifene, a compound of this invention wherein it is the hydrochloride salt of a compound of formula 1, R1 and R3 are hydrogen and R2 is 1-piperidinyl, is a nuclear regulatory molecule. Raloxifene has been shown to bind to the estrogen receptor and was originally thought to be a molecule whose function and pharmacology was that of an anti-estrogen in that it blocked the ability of estrogen to activate uterine tissue and estrogen dependent breast cancers. Indeed, raloxifene does block the action of estrogen in some cells; however in other cell types, raloxifene activates the same genes as estrogen does and displays the same pharmacology, e.g., osteoporosis, hyperlipidemia. As a result, raloxifene has been referred to as an anti-estrogen with mixed agonist-antagonist properties.
The unique profile which raloxifene displays and differs from that of estrogen is now thought to be due to the unique activation and/or suppression of various gene functions by the raloxifene-estrogen receptor complex as opposed to the activation and/or suppression of genes by the estrogen-estrogen receptor complex. Therefore, although raloxifene and estrogen utilize and compete for the same receptor, the pharmacological outcome from gene regulation of the two is not easily predicted and is unique to each.
Generally, the compound is formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered by the intramuscular or intravenous routes. The compounds can be administered CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 transdermally, and may be formulated as sustained release dosage ~orms and the like.
The compounds used in the methods o~ the current invention can be made according to established procedures, such as those detailed in U.S. Patent Mos. 4,133,814, 4,418,068, and 4,380,635 all o~ which are incorporated by re~erence herein. In general, the process starts with a benzo[b]thiophene having a 6-hydroxyl group and a 2-(4-hydroxyphenyl) group. The starting compound is protected, acylated, and deprotected to ~orm the ~ormula I compounds.
Examples of the preparation of such compounds are provided in the U.S. patents discussed above. Optionally substituted phenyl includes phenyl and phenyl substituted once or twice with Cl-C6 alkyl, Cl-C4 alkoxy, hydroxy, nitro, chloro, ~luoro, or tri(chloro or ~luoro)methyl.
The compounds used in the methods o~ this invention ~orm pharmaceutically acceptable acid and base addition salts with a wide variety o~ organic and inorganic acids and bases and include the physiologically acceptable salts which are o~ten used in pharmaceutical chemistry. Such salts are also part o~ this invention. Typical inorganic acids used to ~orm such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sul~uric, phosphoric, hypophosphoric and the like.
Salts derived ~rom organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkanoic ~and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sul~onic acids, may also be used.
Such pharmaceutically acceptable salts thus include acetate, phenylacetate, tri~luoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphth~l~ne-2-benzoate, bromide, isobutyrate, phenylbutyrate, ~-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, caprate, caprylate, chloride, cinn~m~te, citrate, ~ormate, ~umarate, glycollate, heptanoate, hippurate, lactate, malate, CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzene-sulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like.
A preferred salt is the hydrochloride salt.
The pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid. The reactants are generally combined in a mutual solvent such as diethyl ether or benzene. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.
Bases commonly used for formation of salts include ammonium hydroxide and alkali and alkaline earth metal hydroxides, carbonates, as well as aliphatic and primary, secondary and tertiary amines, aliphatic diamines. sases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, methylamine, diethylamine, ethylene diamine and cyclohexylamine.
The pharmaceutically acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more ~m~n~hle to formulation as liquids or emulsions.
Pharmaceutical formulations can be prepared by procedures known in the art. For example, the compounds can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the 'e following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents ~or retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate;
adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols.
The compounds can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes.
Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like. The formulations can be so constituted that they release the active ingredient only or pre~erably in a particular part o~
the intestinal tract, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.
The particular dosage of a compound of formula I
required to inhibit cell-cell adhesion or its effects, or any other use disclosed herein, and according to this invention will depend upon the severity of the condition, the route of administration, and related factors that will be decided by the attending physician. Generally, accepted and effective daily doses will be from about 0.1 to about 1000 mg/day, and more typically from about 50 to about 200 mg/day. Such dosages will be administered ~o a subject in need thereof from once to about three times each day, or more often as CA 022l2339 l997-08-0~
W 096/24384 PCTrUS96/02657 needed to effectively inhibit cell-cell adhesion or its effects, or any other use disclosed herein.
It is usually preferred to administer a compound of formula I in the form of an acid addition salt, as is customary in the administration of pharmaceuticals bearing a basic group, such as the piperidino ring. It is also advantageous to administer such a compound by the oral route.
For such purposes the following oral dosage forms are available.
Formulations In the formulations which follow, ~Active ingredientll means a compound of formula I.
Formulation 1: Gelatin Capsules Hard gelatin capsules are prepared using the following:
Ingredient Quantity (mg/capsule) Active ingredient0.1 - 1000 Starch, NF O - 650 Starch flowable powder 0 - 650 Silicone fluid 3S0 centistokes 0 - 15 The ingredients are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules.
Examples of specific capsule formulations of raloxifene that have been made include those shown below:
CA 022l2339 l997-08-0~
W O 96/24384 PC~rnUS96/02657 Formulation 2: Raloxifene capsule Ingredient Quantity (mg/capsule) Raloxifene Starch, NF 112 Starch ~lowable powder 225.3 Silicone ~luid 350 centistokes 1.7 Formulation 3: Raloxi~ene capsule s IngredientQuantitv (mg/capsule) Raloxifene 5 Starch, NF 108 Starch ~lowable powder225.3 Silicone fluid 350 centistokes 1.7 Formulation 4: Raloxi~ene capsule InaredientQuantitv (ma/capsule) Raloxi~ene 10 Starch, NF 103 Starch flowable powder225.3 Silicone ~luid 350 centistokes 1.7 Formulation 5: Raloxifene capsule IngredientQuantitv (mg~capsule) Raloxi~ene 50 Starch, NF 150 Starch ~lowable powder397 Silicone ~luid 350 centistokes 3.0 The speci~ic ~ormulations above may be changed in compliance with the reasonable variations provided.
CA 022l2339 l997-08-0~
W O 96/24384 PC~rrUS96/026S7 _g _ A tablet formulation is prepared using the ingredients below:
Formulation 6: Tablets Ingredient Quantitv tmg/tablet) Active ingredient 0.1 - 1000 Cellulose, microcrystalline 0 - 650 Silicon dioxide, fumed0 - 650 Stearate acid 0 - 15 The components are blended and compressed to form tablets.
Alternatively, tablets each containing 0.1 - 1000 mg of active ingredient are made up as follows:
Formulation 7: Tablets Inaredient Quantitv (ma/tablet) Active ingredient 0.1 - 1000 Starch 45 Cellulose, microcrystalline 35 Polyvinylpyrrolidone 4 (as 10% solution in water) Sodium carboxymethyl cellulose 4.5 Magnesium ctearate 0 5 Talc The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
The solution o~ polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50~-60~ C
- ~ and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 to the granules which, after mixing, are compressed on a tablet machine to yield tablets.
Suspensions each containing 0.1 - 1000 mg of medicament per 5 mL dose are made as follows:
Formulation 8: Suspensions Inaredient Quantity (mg/5 ml) Active ingredient 0.1 - 1000 mg Sodium carboxymethyl cellulose 50 mg Syrup 1.25 mg Benzoic acid solution 0.10 mL
Flavor q.v.
Color ~q.v.
Puri~ied water to 5 mL
The medicament is passed through a No. 45 me~sh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.
In vitro Cell Adhesion AssaYs Human Umbilical Vein Endothelium Cells (H W EC) or Human Aortic Endothelium (HAE) were obtained from Clonetics (San Diego) and grown in the EBM medium supplied by Clonetics. Cells were plated in 96 well plates at a density to obtain confluent monolayers following overnight incubation at 37 degrees C. Test compound was added and incubated in serum-free medium for 8-20 hours. Monolayers were then incubated with or without 2ng/ml IL-1 or with 20 nanograms Tumor Necrosis Factor (TNF) for 4 to 24 hours prior to the binding assay in a total volume of 75 to 100 microliters-in the presence o~ the test compound. Following incubations, CA 02212339 1997-08-0~
tritium-labelled U937 cells were added in 50 microliter ~ volumes at from 1 to 3 x 10(6) cells per well. The U937 cells were tritium labelled by the addition of 3H-thymidine - to a final concentration of 1 microcurie per milliliter, followed by 18 to 20 hours incubation. Cells were washed with PBS prior to use to remove excess label. After a 20 minute incubation of the labeled U937 cells with the endothelial cells, the wells were aspirated and washed four times with calcium-containing PBS. The monolayer and adherent U937 cells were solubilized by the addition of 0.25 SDS/0.1 N NaOH for 5 minutes with agitation. The level of binding was determined by scintillation counting of the solubilized cells.
Anticoaaulant activitv assaY
Confluent cultures of IL1-treated (2 ng/ml) or untreated human endothelial cells in 96 well plates were washed once with HBSS to remove serum proteins and incubated with serum-free medium (DMEM/F-12 medium, 20 mM-HEPES, pH 7.5, 50 mg/ml gentamicin, 1 mg/ml human transferrin and 1 mg/ml bovine insulin. ) containing 400 nM-recombinant human protein C and 10 nM human thrombin. Cells were incubated at 37~C, and at various times medium was removed and added to an equal volume of a solution of 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mg/ml sSA and 10 U/ml Hirudin. The samples were incubated in the hirudin-contain buffer for 5 min to inhibit thrombin activity. The amount of activated protein C generated was determined by the addition of chromogenic substrate (S-2366) to a final concentration of 0.75 mM, and measuring the change in absorbance units/minute at ~05 nm in a ThermoMax kinetic micro-titer plate reader (Molecular Devices). In all experiments, samples of the protein C/thrombin solution were incubated in wells without cells to determine basal levels of = = = ~ ~ = --CA 02212339 1997-08-0~
W 096/24384 PCTrUS96/02657 thrombin-catalyzed activation of protein C. The amount of activated protein C generated is expressed as the absorbance (mOD) per minute per microgram o~ cellular protein.
Results Human umbilical vein endothelial cells (H W EC) were treated with compound A where Rl and R3 are hydrogen and R3 is pyrrolidino, concurrent to the induction of adhesion molecule expression by TNF. As shown in Table I, the presence of 100 nM of compound A resulted in an approximate 40% reduction in the level of cell-cell adhesion in this assay. When cells were pretreated with only 10nM of compound A for approximately 20 hours before induction with TNF, an approximate 65 % reduction in adhesion was observed (TabIe 2). We also treated both HUVECs and human aortic endothelial cells (HAEC) with ILl, another inflammatory mediator to induce adhesion molecule expression in the presence of lOnM compound A. As shown in Table 3, compound A effectively inhibited the ILl-induction of adhesion in both cell Lines. Thus compound A can block the induction of adhesion molecule expression mediated by two independent means and in both venous and arterial cells.
As further evidence for the ability of this compound to modulate the functional properties of the endothelium, we measured the ability of the endothelial cells to activate human protein C, a natural regulatory function that is down regulated during states of endothelial dysfunction. AS shown in Table 4, ILl treatment of the cells significantly reduced the capability of the endothelium to support protein C
generation. However, following treatment of the cells with compound A, the suppression of this ~unction by ILl was essentially eliminated. The above data indicate that compound A protects the cells from activation of inflammatory and procoagulant activities.
CA 022l2339 l997-08-05 W 096/24384 PCTrUS96/02657 Table 1. E~ect of Compound A on adhesion of U937 cells to TNF-activated human umbilical vein endothelial cells (HUVEC) Condition Percent Binding Activity a Untreated control o + 7.5 TNF treated 100 + 9. 5 TNF plus compound A (100 nM) 62 + 17 aThe level of binding is expressed as the percent of the number of U937 cells bound to the endothelium before and after TNF induction.
Table 2. E~ect o~ pretreatment with compound A on adhesion o~ U937 cells to TNF-activated human umbilical vein endothelial cells (HUVEC) Condition ~ Percent Binding Activity a Untreated control 0 + 20 TNF treated 100 + 16 TNF plus compound A (10 nM) 34 + 8 CA 022l2339 l997-08-0~
W 096/24384 PCTnUS96/02657 aThe level of binding is expressed as the percent of the number of U937 cells bound to the endothelium before and after TNF induction.
Table 3. E~ect o~ pretreatment with compound A on adhesion o~ U937 cells to ILl -activated human aortic endothelial cells (HAEC) and human umbilical vein endothelial cells (HUVEC) Condition Percent 3inding Activitya to H W EC HAEC
ILl-treated 100 + 14 100 + 8 ILl plus compound A (10 nM) 18 + 13 54 i 7 aThe level of binding is expressed as the percent of the number of U937 cells bound to the endothelium before and after ILl induction.
Table 4. Ef~ect o~ compound A on thrombin-catalyzed activation o~ human protein C on endothelial cells treated with IL-l Condition Level of protein C produced (mOD/min/ug) untreated control 8.8 i 1. 4 l-treated 3.7 + 0.4 ILl plus compound A 7.6 + .6
Claims (6)
1. A method of inhibiting cell-cell adhesion comprising administering to a human in need thereof an effective amount of a compound having the formula (I) wherein R1 and R3 are independently hydrogen, -CH3, , wherein Ar is optionally substituted phenyl;
R2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
R2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
2. The method of Claim 1 wherein said compound is the hydrochloride salt thereof.
3. The method of Claim 1 wherein said compound is or its hydrochloride salt.
4. A method to inhibit inflammatory and disrupted normal coagulation process in patients with disorders of the vascular endothelium comprising administering to a patent in need thereof an effective amount of a compound having the formula ( I ) wherein R1 and R3 are independently hydrogen, -CH3, , wherein Ar is optionally substituted phenyl;
R2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
R2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
5. The method of Claim 4 wherein said compound is the hydrochloride salt thereof.
6. The method of Claim 4 wherein said compound is or its hydrochloride salt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/385,934 US5484808A (en) | 1995-02-09 | 1995-02-09 | Methods of inhibiting cell-cell adhesion |
| US08/385,934 | 1995-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2212339A1 true CA2212339A1 (en) | 1996-08-15 |
Family
ID=23523494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002212339A Abandoned CA2212339A1 (en) | 1995-02-09 | 1996-02-09 | Methods of inhibiting cell-cell adhesion |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US5484808A (en) |
| EP (1) | EP0726071A2 (en) |
| JP (1) | JPH10513475A (en) |
| KR (1) | KR19980702079A (en) |
| CN (1) | CN1072931C (en) |
| AU (1) | AU693021B2 (en) |
| CA (1) | CA2212339A1 (en) |
| CZ (1) | CZ286448B6 (en) |
| HU (1) | HUP9801323A3 (en) |
| IL (1) | IL117079A (en) |
| MY (1) | MY132251A (en) |
| NO (1) | NO973635L (en) |
| NZ (1) | NZ305072A (en) |
| RU (1) | RU2179021C2 (en) |
| UA (1) | UA43391C2 (en) |
| WO (1) | WO1996024384A1 (en) |
| ZA (1) | ZA961076B (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6515009B1 (en) * | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| WO1996040098A2 (en) * | 1995-06-07 | 1996-12-19 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
| US20030083733A1 (en) * | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
| US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
| US5747509A (en) * | 1996-06-03 | 1998-05-05 | Schering Aktiengesellschaft | Method for lowering plasma levels of lipoprotein(a) |
| US5773432A (en) * | 1996-10-30 | 1998-06-30 | Schering Aktiengesellschaft | Method for lowering plasma levels of lipoprotein(a) |
| AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| US6008232A (en) * | 1997-08-20 | 1999-12-28 | Eli Lilly And Company | Methods for preventing headaches |
| EP1067128A4 (en) * | 1998-04-01 | 2001-11-21 | Ono Pharmaceutical Co | Fused thiophene derivatives and drugs containing the same as the active ingredient |
| AU777770C (en) | 1999-05-04 | 2005-11-10 | Strakan International Limited | Androgen glycosides and androgenic activity thereof |
| US6359015B1 (en) | 2000-02-28 | 2002-03-19 | The United States Of America As Represented By The Department Of Veterans Affairs | Method for antagonizing inhibition effects of alcohol on cell adhesion |
| US20040121309A1 (en) * | 2002-12-06 | 2004-06-24 | Ecker David J. | Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues |
| US7666588B2 (en) | 2001-03-02 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy |
| US20030027135A1 (en) * | 2001-03-02 | 2003-02-06 | Ecker David J. | Method for rapid detection and identification of bioagents |
| US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
| JP3887588B2 (en) * | 2002-08-30 | 2007-02-28 | 株式会社リガク | Stress measurement method by X-ray diffraction |
| US6977272B2 (en) * | 2002-10-16 | 2005-12-20 | President And Fellows Of Harvard College | Method for antagonizing inhibition effects of alcohol on cell adhesion |
| CA2508726A1 (en) | 2002-12-06 | 2004-07-22 | Isis Pharmaceuticals, Inc. | Methods for rapid identification of pathogens in humans and animals |
| US7964343B2 (en) * | 2003-05-13 | 2011-06-21 | Ibis Biosciences, Inc. | Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
| US8546082B2 (en) | 2003-09-11 | 2013-10-01 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
| US7956175B2 (en) | 2003-09-11 | 2011-06-07 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
| US8097416B2 (en) | 2003-09-11 | 2012-01-17 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
| US20050266411A1 (en) * | 2004-05-25 | 2005-12-01 | Hofstadler Steven A | Methods for rapid forensic analysis of mitochondrial DNA |
| WO2006135400A2 (en) | 2004-08-24 | 2006-12-21 | Isis Pharmaceuticals, Inc. | Methods for rapid identification of recombinant organisms |
| CA2616281C (en) * | 2005-07-21 | 2014-04-22 | Isis Pharmaceuticals, Inc. | Methods for rapid identification and quantitation of mitochondrial dna variants |
| CN107412248A (en) | 2016-05-24 | 2017-12-01 | 中国医学科学院药物研究所 | Application of the THPA in treatment vascular inflammation or improvement function of vascular endothelium |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| JP3157882B2 (en) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | New benzothiophene derivatives |
| US5356926A (en) * | 1992-02-24 | 1994-10-18 | Warner-Lambert Company | 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo [β]thiophene-2-carboxamides as inhibitors of cell adhesion |
| TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
| UA32427C2 (en) * | 1993-10-15 | 2000-12-15 | Елі Ліллі Енд Компані | The use of benzothiophene or pharmaceutical acceptable salts or solvate thereof for inhibition of angiogenesis and/or angiogenic diseases |
| US5457113A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell proliferation and restinosis |
| US5476862A (en) * | 1993-12-21 | 1995-12-19 | Eli Lilly And Company | Methods of increasing thrombomodulin expression |
| US5441965A (en) * | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
| US5574047A (en) * | 1993-12-21 | 1996-11-12 | Eli Lilly And Company | Methods of inhibiting imperfect tissue repair |
-
1995
- 1995-02-09 US US08/385,934 patent/US5484808A/en not_active Expired - Fee Related
- 1995-04-14 US US08/422,295 patent/US5496851A/en not_active Expired - Fee Related
-
1996
- 1996-02-08 IL IL11707996A patent/IL117079A/en not_active IP Right Cessation
- 1996-02-09 WO PCT/US1996/002657 patent/WO1996024384A1/en not_active Application Discontinuation
- 1996-02-09 HU HU9801323A patent/HUP9801323A3/en unknown
- 1996-02-09 CA CA002212339A patent/CA2212339A1/en not_active Abandoned
- 1996-02-09 KR KR1019970705474A patent/KR19980702079A/en not_active Application Discontinuation
- 1996-02-09 ZA ZA9601076A patent/ZA961076B/en unknown
- 1996-02-09 MY MYPI96000491A patent/MY132251A/en unknown
- 1996-02-09 EP EP96300876A patent/EP0726071A2/en not_active Withdrawn
- 1996-02-09 CZ CZ19972482A patent/CZ286448B6/en not_active IP Right Cessation
- 1996-02-09 JP JP8524495A patent/JPH10513475A/en not_active Withdrawn
- 1996-02-09 CN CN96191839A patent/CN1072931C/en not_active Expired - Fee Related
- 1996-02-09 NZ NZ305072A patent/NZ305072A/en unknown
- 1996-02-09 AU AU52996/96A patent/AU693021B2/en not_active Ceased
- 1996-02-09 UA UA97084166A patent/UA43391C2/en unknown
- 1996-02-09 RU RU97114956/14A patent/RU2179021C2/en active
-
1997
- 1997-08-06 NO NO973635A patent/NO973635L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU5299696A (en) | 1996-08-27 |
| NO973635D0 (en) | 1997-08-06 |
| NZ305072A (en) | 2000-07-28 |
| CN1173821A (en) | 1998-02-18 |
| MY132251A (en) | 2007-09-28 |
| UA43391C2 (en) | 2001-12-17 |
| ZA961076B (en) | 1997-08-11 |
| EP0726071A2 (en) | 1996-08-14 |
| US5484808A (en) | 1996-01-16 |
| JPH10513475A (en) | 1998-12-22 |
| CZ248297A3 (en) | 1998-06-17 |
| IL117079A (en) | 1999-12-31 |
| AU693021B2 (en) | 1998-06-18 |
| CN1072931C (en) | 2001-10-17 |
| IL117079A0 (en) | 1996-06-18 |
| NO973635L (en) | 1997-09-29 |
| HUP9801323A3 (en) | 1999-09-28 |
| WO1996024384A1 (en) | 1996-08-15 |
| MX9706072A (en) | 1997-10-31 |
| US5496851A (en) | 1996-03-05 |
| CZ286448B6 (en) | 2000-04-12 |
| RU2179021C2 (en) | 2002-02-10 |
| HUP9801323A2 (en) | 1999-05-28 |
| KR19980702079A (en) | 1998-07-15 |
| EP0726071A3 (en) | 1996-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5484808A (en) | Methods of inhibiting cell-cell adhesion | |
| US5622975A (en) | Methods for inhibiting vascular smooth muscle cell migration | |
| CA2118095A1 (en) | Methods for inhibiting smooth muscle cell proliferation and restinosis | |
| US5691355A (en) | Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs | |
| US5610166A (en) | Methods for inhibiting angiogenesis | |
| US5418252A (en) | Method for inhibiting cartilage degradation | |
| US5663184A (en) | Methods of inhibiting CNS problems in post-menopausal women | |
| US5593987A (en) | Methods of inhibiting breast disorders | |
| US5698572A (en) | Methods of inhibiting turner's syndrome | |
| US5843974A (en) | Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se | |
| AU716655B2 (en) | Methods of inhibiting plasminogen activator inhibitor 1 | |
| US5980938A (en) | Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1) | |
| MXPA97006072A (en) | Methods of inhibition of cell-cell adhesion | |
| EP0729754A2 (en) | 2-Phenyl-3-aroylbonzothiophenes for inhibiting estrogen positive tumors of the brain or CNS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |